Earlier today, Roche announced that crenezumab, a passive immunotherapy, discontinue the two ongoing phase III studies in early Alzheimer patients. We didn’t view crenezumab as a direct competitor to Alzinova’s lead candidate, ALZ-101, and argue that the failure further strengthens the amyloid-β oligomer-specific approach of ALZ-101.